Autologous vs Donor Stem Cells: What Are the Differences?

The Core Distinction

When families first encounter stem cell therapy, one of the most important questions to ask is: where do the cells come from? The answer divides all stem cell protocols into two fundamentally different categories — autologous and allogeneic — with meaningful differences in safety, ethics and clinical application.

Autologous: The Child's Own Cells

In an autologous protocol, stem cells are collected from the patient's own body — typically from bone marrow (via aspiration from the pelvic bone) or from adipose tissue (via a minor lipoaspiration procedure). These cells are then processed in a GMP-certified laboratory and returned to the same child through intravenous or intrathecal administration.

The primary advantage is immunological: because the body recognises its own cells, the risk of immune rejection approaches zero. There is no need for immunosuppressant medications after the procedure. There is also no risk of transmitting infections from a donor, and no ethical questions about the origin of the cells.

For paediatric ASD cases, autologous therapy represents the most straightforward safety profile available in stem cell medicine.

Allogeneic: Cells from a Donor

In an allogeneic protocol, cells come from a third-party donor — most commonly umbilical cord blood collected at birth, or a matched bone marrow donor. These cells are processed and banked for later use.

Allogeneic therapy has legitimate clinical applications, particularly in oncology, where it has been used for decades. However, for paediatric ASD — a non-life-threatening condition in an immunologically active child — the risk-benefit profile is more complex.

The key risks include:

**Immune rejection**: The recipient's immune system may recognise donor cells as foreign and mount a response

**Graft-versus-host disease (GvHD)**: In this serious complication, donor immune cells attack the recipient's own tissues. Even with careful HLA matching, this risk cannot be entirely eliminated

**Immunosuppression requirements**: To reduce rejection risk, patients typically require immunosuppressant drugs, which carry their own side effect profile

**Donor-to-recipient infection transmission**: Although rare with properly screened donors, the risk exists

What About Cord Blood Banking?

Some families who banked their child's cord blood at birth ask whether this could be used. Cord blood from the child's own birth is autologous and avoids the rejection concerns of donor cord blood. However, the cell count in a typical cord blood unit may be limited, and cell viability after years of cryopreservation varies. Each case requires individual assessment.

Why Vellorian Health Uses Exclusively Autologous Protocols

For paediatric ASD, we believe the autologous approach represents the most defensible standard of care given the current evidence. The safety profile is well-characterised, the ethical questions are minimal, and the procedure is well-tolerated under appropriate sedation.

We do not use allogeneic protocols for ASD. This is not because allogeneic therapy is inherently wrong, but because the risk-benefit calculation for a growing child with a non-life-threatening condition does not support it in our clinical judgement.

Questions to Ask Any Clinic

Is the protocol autologous or allogeneic?

If autologous: from which tissue will cells be collected?

If allogeneic: what HLA matching is performed, and what is the protocol for monitoring GvHD?

What immunosuppression is required, and for how long?

What is the track record with paediatric ASD cases specifically?

The source of the cells is not a detail. It is the foundation of the safety profile.